StemCells finds early data from spinal cord injury trial promising

StemCells CEO Martin McGlynn.

Early data from an early-stage trial in spinal cord patients by StemCells Inc. indicated that two of three patients with the worst kind of spinal cord injuries started recovering feeling. The Newark company (NASDAQ: STEM), which is developing human neural stem cells, is the first to report data from a stem cells trial in spinal cord injuries, a spokeswoman said.